FDA Proposes 'No Clinical Need' to Compound GLP-1 Drugs From Bulk Ingredients
The agency's proposed determination would bar outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk active ingredient, unless a new shortage intervenes.
On May 1, 2026, the Food and Drug Administration published a proposed determination that could reshape the compounded weight-loss and diabetes market: it tentatively found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk active ingredient. The notice (Docket No. FDA-2018-N-3240) proposes to leave all three GLP-1 receptor agonists off the section 503B Bulks List.
That list matters because of how federal law channels compounding. Under section 503B of the Federal Food, Drug, and Cosmetic Act, a registered outsourcing facility generally may not compound a drug from a bulk substance unless the substance appears on the 503B Bulks List, or the finished drug is on FDA’s shortage list at the time it is made. Semaglutide and tirzepatide were both on that shortage list during the supply crunch (semaglutide from 2022 to 2025, tirzepatide from 2022 to 2024) but have since come off it. With the shortage door closed, listing became the compounders’ remaining path. FDA is now proposing to close that one too.
The rationale turns on a specific reading of “clinical need.” FDA applies a threshold, two-part test: is there an attribute of the FDA-approved product that makes it medically unsuitable for some patients, and would the compounded version address that attribute; and must the drug be made from bulk rather than from an approved product? The agency wrote that it “did not answer ‘yes’ to both of the threshold questions” for any of the three substances, and so did not proceed to weigh safety or effectiveness.
Nominators, among them the Outsourcing Facilities Association and BPI Labs, had argued for sublingual, buccal, and oral routes; for “microdosing” and higher-than-approved strengths; for propylene-glycol-free injections; and for combination products mixing the peptide with pyridoxine or an antiemetic. FDA rejected each, concluding the nominations described preferences, convenience, or supply concerns rather than an attribute making the approved drugs medically unsuitable. The agency said it does not treat shortages, backorders, cost, or the convenience of a ready-to-use form as “clinical need.”
Novo Nordisk (semaglutide and liraglutide) and Eli Lilly (tirzepatide) had filed comments opposing the nominations; the branded manufacturers’ position prevailed at the proposal stage.
This is a proposal, not a final rule. FDA opened a 60-day comment window closing June 30, 2026, then, in a notice published June 26, granted a 30-day extension to July 30, 2026, after a request argued the original period was too short for “complex clinical, public health, and legal issues.” As the law firm Epstein Becker & Green noted in a May 6 analysis, liraglutide injection’s continued presence on the shortage list preserves a narrow, temporary compounding pathway for that drug alone; if the determination is finalized, compounded semaglutide and tirzepatide from bulk would be off the table absent a new shortage.